
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 1.060 | 1.350 | 0.290 |
Shares | 98.950 | 98.950 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 15.269 | 17.149 |
Price to Book | 3.786 | 3.706 |
Price to Sales | 5.113 | 5.005 |
Price to Cash Flow | 13.560 | 14.761 |
Dividend Yield | 0.843 | 0.525 |
5 Years Earnings Growth | 9.085 | 8.825 |
Number of long holdings: 53
Number of short holdings: 5
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Vertex | US92532F1003 | 8.44 | 459.81 | -0.75% | |
Alnylam | US02043Q1076 | 8.08 | 320.53 | -1.28% | |
Neurocrine | US64125C1099 | 6.05 | 132.02 | -1.56% | |
Gilead | US3755581036 | 5.54 | 108.22 | -0.53% | |
AbbVie | US00287Y1091 | 4.91 | 189.26 | -1.12% | |
Amgen | US0311621009 | 4.43 | 294.83 | -1.15% | |
Sandoz | CH1243598427 | 3.96 | 45.76 | +1.85% | |
Guardant Health | US40131M1099 | 3.96 | 46.46 | -1.73% | |
Roivant Sciences Ltd Ordinary Shares | - | 3.59 | - | - | |
Blueprint Medicines Corp | US09627Y1091 | 3.54 | 129.46 | +0.00% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU1313519925 | 6.37B | 0.80 | -2.50 | 4.71 | ||
LU1300848345 | 6.37B | 0.92 | -2.20 | - | ||
LU1323611266 | 4.17B | 4.17 | 7.52 | - | ||
LU1520716801 | 4.17B | 2.07 | 8.35 | - | ||
UBS lux Eq SICAV USAGrwth USD Q Acc | 3.31B | 6.45 | 24.37 | 15.06 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review